Coya appoints former Bayer Pharma CEO Dieter Weinand to board of directors

Coya Therapeutics, Inc.

Board expands to 6 members; Weinand named Class I director effective August 18, 2023.
Weinand granted option to buy 10,000 shares at $3.43, vesting on one-year anniversary.
He joins audit and nominating/governance committees, committees expanded to 4 members.
Weinand is former CEO and Chairman of Bayer Pharma AG; current chairman of Replimune and others.
Coya expects to leverage his 25+ years of pharma experience for strategic guidance.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dieter Weinand

Class I Director

COYA · Coya Therapeutics, Inc.

Effective: 2023-08-18
Filed: August 21, 2023, 7:59 PM ET

On August 18, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to six directors from five, and appointed Dieter Weinand as a Class I director to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dieter Weinand was appointed as Class I Director at Coya Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On August 18, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to six directors from five, and appointed Dieter Weinand as a Class I director to fill the newly created vacancy.

View on SEC.gov

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-217039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.